NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 80 resultados LastUpdate Última actualización 03/10/2022 [08:36:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 4 nextPage   por página


QUINAZOLINE COMPOUND AND USE OF PHARMACEUTICAL COMPOSITION

NºPublicación: WO2022199373A1 29/09/2022

Solicitante:

SHANG YINGLI PHARMACEUTICAL CO LTD [CN]

CN_115120596_PA

Resumen de: WO2022199373A1

Disclosed are a quinazoline compound and the use of a pharmaceutical composition. The substance X of the present invention is the quinazoline compound, as represented by formula A; a pharmaceutically acceptable salt thereof; and a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention comprises the substance X and a pharmaceutical excipient. The substance X or the pharmaceutical composition provided in the present invention has a good treatment effect on B-cell hematologic neoplasms, and especially has a good treatment effect on follicular lymphoma, and has high efficiency and a good degree of safety.

traducir

METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS

NºPublicación: WO2022200303A1 29/09/2022

Solicitante:

INST NAT SANTE RECH MED [FR]
ASSIST PUBLIQUE HOPITAUX PARIS APHP [FR]
UNIV PARIS CITE [FR]
UNIV PARIS VAL DE MARNE [FR]

Resumen de: WO2022200303A1

T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sezary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sezary cells and showed the expression of CCR8 (CD198) by Sezary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas.

traducir

Combinations

NºPublicación: AU2021268195A1 29/09/2022

Solicitante:

RECURIUM IP HOLDINGS LLC

WO_2021226263_A1

Resumen de: AU2021268195A1

Disclosed herein are combination therapies of Bcl-2 inhibitors (Compound (A), along with pharmaceutically acceptable salts thereof) and CDK 4/6 inhibitors (Compound (B), along with pharmaceutically acceptable salts thereof) for treating a disease or condition, such as a cancer, including breast cancer and leukemia.

traducir

CD19-directed chimeric antigen receptor T cell compositions and methods and uses thereof

NºPublicación: AU2021220875A1 29/09/2022

Solicitante:

JUNO THERAPEUTICS INC

WO_2021163391_A1

Resumen de: AU2021220875A1

Provided in some aspects are compositions of cells for treating subjects with disease and conditions such as non-Hodgkin's lymphoma (NHL), and related methods, compositions, uses and articles of manufacture. In some embodiments, the disease or condition is a B-cell non-Hodgkin lymphoma (B-cell NHL). The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) for targeting an antigen, such as CD 19, on cells of the lymphoma.

traducir

Use of pyrido1,2-apyrimidinone compound in treating lymphoma

NºPublicación: AU2021218925A1 29/09/2022

Solicitante:

CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD

Resumen de: AU2021218925A1

The present application belongs to the field of medicinal chemistry, and relates to a use of a pyrido[1,2-a]pyrimidinone compound in treating lymphoma. Specifically, the present application relates to a pyrido[1,2-a]pyrimidinone compound or a pharmaceutical composition thereof for treating lymphoma, and a method or use of a pyrido[1,2-a]pyrimidinone compound in treating lymphoma.

traducir

DISCERNING BRAIN CANCER TYPE

NºPublicación: US2022308058A1 29/09/2022

Solicitante:

DXCOVER LTD [GB]

CN_114599956_A

Resumen de: US2022308058A1

The present invention relates to methods of determining whether a subject suspected of having a brain tumour has a glioma or a lymphoma. The invention also relates to a diagnostic kit for determining whether a subject suspected of having a brain tumour has a glioma or a lymphoma and a method of facilitating the selection of treatment for a subject suspected of having a brain tumour.

traducir

2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS

NºPublicación: US2022306675A1 29/09/2022

Solicitante:

NUCANA PLC [GB]

CN_111909231_A

Resumen de: US2022306675A1

The present invention relates to chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositions comprising the compounds. The compounds may, in particular, be useful in the treatment of leukaemia, lymphoma and/or solid tumours in homo sapiens. The compounds are derivatives of cordycepin (3′-deoxyadenosine).

traducir

CANNABINOID RECEPTOR MODULATORS

NºPublicación: US2022306586A1 29/09/2022

Solicitante:

ARENA PHARM INC [US]

EP_4036089_A1

Resumen de: US2022306586A1

The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

traducir

METHODS OF TREATING ACUTE MYELOID LEUKEMIA WITH FARNESYLTRANSFERASE INHIBITORS

NºPublicación: US2022305001A1 29/09/2022

Solicitante:

KURA ONCOLOGY INC [US]

WO_2020223583_A1

Resumen de: US2022305001A1

The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating Acute Myeloid Leukemia in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the expression level of FLT3LG.

traducir

Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds

NºPublicación: AU2021244255A1 29/09/2022

Solicitante:

ACLARIS THERAPEUTICS INC

AU_2021244609_PA

Resumen de: AU2021244255A1

The present disclosure provides a crystalline form of the methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compound of the structure: XRPD, TGA, and DSC data on the crystalline form, as well as methods preparing the crystalline form, including a multi-kilo scale preparation. Also provided are pharmaceutical compositions and methods of treating p38 mediated diseases, such as lymphoma and auto-inflammatory disease, including rheumatoid arthritis. and methods of maximizing the yield thereof comprising administering of the compound. Also provided is a method of maximizing the yield of said compound via a recycling procedure.

traducir

METAL CHELATOR COMBINATION THERAPY FOR THE TREATMENT OF CANCER

NºPublicación: US2022305005A1 29/09/2022

Solicitante:

UNIV TEXAS [US]

JP_2022523672_A

Resumen de: US2022305005A1

Provided are methods for the treatment of cancers including leukemias, that utilize combination therapies. In some embodiments, a metal chelator is administered to a patient in combination with a cancer therapy, zinc, selenium, magnesium, and vitamin C to treat the cancer. In some embodiments, increased efficacy of the cancer therapy can be observed, and/or lower dosages of a chemotherapeutic may be administered to the subject as a result of the combination therapy.

traducir

INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7)

NºPublicación: US2022305014A1 29/09/2022

Solicitante:

SYROS PHARMACEUTICALS INC [US]

US_2021379065_A1

Resumen de: US2022305014A1

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

traducir

Bispecific Anti-BCMA x Anti-CD3 Antibodies and Uses Thereof

NºPublicación: US2022306758A1 29/09/2022

Solicitante:

REGENERON PHARMA [US]

JP_2021531005_A

Resumen de: US2022306758A1

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.

traducir

SMALL MOLECULES AND THEIR USE AS MALT1 INHIBITORS

NºPublicación: WO2022204386A2 29/09/2022

Solicitante:

UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION [US]
UNIV MICHIGAN REGENTS [US]
LUCAS PETER C [US]
MCALLISTER LINDA M [US]
KANG HEEJAE [US]
CHEN BEIBEI [US]
MAURER LISA [US]
HU DONG [US]
CHENG JING [US]
KLEI LINDA [US]
NIKOLOVSAKA COLESKA ZANETA [US]

Resumen de: WO2022204386A2

Small molecule inhibitors that block the interaction between B-cell lymphoma 10 protein (BCL10) and mucosa- associated lymphoid tissue lymphoma translocation protein 1 (MALT1), thereby inhibiting both the protease and scaffolding activities of MALT1, and MALT1- dependent downstream signaling, including IL-6 and IL-10 secretion by B-cell lymphoma cells and IL-2 transcription and secretion by Jurkat T cells.

traducir

CARBONIC ANHYDRASE 1 (CA1) INHIBITORS FOR THE TREATMENT OR PREVENTION OF MYELOPROLIFERATIVE DISORDERS AND OTHER HEMATOPOIETIC MALIGNANCIES, AND AS BIOMARKER OF MYELOPROLIFERATIVE DISORDERS AND OTHER HEMATOPOIETIC MALIGNANCIES

NºPublicación: WO2022200613A2 29/09/2022

Solicitante:

COMMISSARIAT ENERGIE ATOMIQUE [FR]
INST NAT SANTE RECH MED [FR]
UNIV PARIS CITE [FR]
UNIV PARIS SACLAY [FR]

EP_4062909_A1

Resumen de: WO2022200613A2

The invention relates to the treatment or prevention of myeloproliferative disorders and other hematopoietic malignancies. Herein is described a carbonic Anhydrase 1 (CA1) inhibitor; for use in a method for treating or preventing a myeloproliferative disorder, an acute myeloid leukemia (AML) and/or a primary or secondary myelofibrosis. Herein is further described the use of carbonic Anhydrase 1 as a biomarker for myeloproliferative disorders and other hematopoietic malignancies; and/or as a biomarker of the efficacy of compounds for treating or preventing said conditions.

traducir

USE OF THE SESQUITERPENE LACTONE TOMENTOSIN IN THE TREATMENT OF TUMORS CAUSED BY LYMPHOID CELL LINES

NºPublicación: WO2022200926A1 29/09/2022

Solicitante:

UNIV DEGLI STUDI DI SASSARI [IT]

Resumen de: WO2022200926A1

The present invention relates to the use of sesquiterpene lactones isolated from extracts of Inula viscosa in the treatment of tumors; in particular, the use of the sesquiterpene lactone Tomentosin in the treatment of lymphoproliferative tumoral diseases, such as, for example, myelomas and/or lymphomas, caused by lymphoid cell lines.

traducir

CD22 targeting-moiety for the treatment of B-cell acute lymphoblastic leukemia (B-ALL)

NºPublicación: AU2021233158A1 29/09/2022

Solicitante:

FUNDACIO INST DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
INST CATALANA DE RECERCA I ESTUDIS AVANCATS ICREA
UNIV BARCELONA
FUNDACIO INST DINVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL IGTP
ONECHAIN IMMUNOTHERAPEUTICS S L

WO_2021180890_A1

Resumen de: AU2021233158A1

The present invention provides therapeutics for the treatment of CD22-positive cancers such as B-cell acute lymphoblastic leukemia (B-ALL). In particular, the present invention provides an anti-CD22 monoclonal antibody whose scFv as a part of chimeric antigen receptors (CAR) T-cells can target the first Ig extracellular domain of the CD22 antigen, the farthest domain from the membrane, for use in the treatment of CD22-positive cancers.

traducir

COMBINATION THERAPY WITH AN ANTI-CD19 ANTIBODY AND A NITROGEN MUSTARD

NºPublicación: EP4062936A1 28/09/2022

Solicitante:

MORPHOSYS AG [DE]

ES_2909722_T3

Resumen de: EP4062936A1

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

traducir

METHOD FOR DETECTING CANCER BONE METASTASIS AND DETECTION REAGENT

NºPublicación: EP4063845A1 28/09/2022

Solicitante:

UNIV OSAKA [JP]
TOSOH CORP [JP]

BR_112022009397_A2

Resumen de: EP4063845A1

A problem to be addressed by the present invention is to provide: a method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) in a simple and highly accurate manner; and a reagent that can be used in the method. Bone metastasis of cancer (excluding castration resistant prostate cancer) is detected by measuring an intact growth and differentiation factor 15 (GDF15) propeptide level, a GDF15 propeptide fragment level, and the total of an intact GDF15 propeptide level and a GDF15 propeptide fragment level in a sample. The above described method for detecting bone metastasis of cancer includes a method for detecting bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma. Further, the reagent for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) includes an antibody that specifically recognizes GDF15 propeptide.

traducir

METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

NºPublicación: EP4061967A1 28/09/2022

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV COTE D'AZUR [FR]
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
UNIV COLUMBIA [US]

WO_2021099573_A1

Resumen de: WO2021099573A1

In the present invention, inventors have used high throughput sequencing to identify novel mutations in ABCA1 in CMML patient samples. Further studies in a mouse model of myelomonocytic leukemia driven by hematopoietic Tet2 deficiency have shown that these somatic mutations abrogate the tumor suppressor function of WT ABCA1, resulting in the failure to suppress canonical IL3-receptor beta signaling-driven myelopoiesis. The loss of the myelo-suppressive function of ABCA1 mutants can be overcome by raising HDL levels through overexpression of the human apolipoprotein A-1 (apoA-1) transgene. Inventors have also shown that both IL-3Rbeta blocking antibody and cyclodextrin prevented the proliferation of ABCA1 mutant-transduced Tet2 deficient BM cells similar to the effect of ABCA1-WT overexpression. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from CMML comprising the step identifying at least one ABCA1 and to a method for treating said subject with HDL/ABCA recombinant (ApoA-1); cylodextrin and/or anti-IL-3Rbeta antibody.

traducir

INHIBITORS OF ADRENOMEDULLIN FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA BY ERADICATING LEUKEMIC STEM CELLS

NºPublicación: EP4061944A1 28/09/2022

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV TOULOUSE 3 PAUL SABATIER [FR]

WO_2021099600_A1

Resumen de: WO2021099600A1

The emergence of cells with drug resistant and/or stem cell features might explain frequent relapses and the poor outcome of patients with acute myeloid leukemia (AML). LSCs are heterogeneous for their phenotypes and their sensitivity to chemotherapeutic agents in vivo. Using in silico and functional approaches, the inventors uncovered that CALCRL is overexpressed in LSCs compared with normal hematopoietic cells. They further demonstrated that the CALCRL ligand adrenomedullin (ADM) is highly expressed in AML cells and that increased transcript level was markedly associated with decreased complete remission rates, 5-year overall and event7free survival. The inventors also showed that CALCRL depletion strongly affected leukemic growth in vivo and increased mice survival. Targeting ADM phenocopies the biological and anti-leukemic effects of the CALCRL depletion. These data highlight the critical role of ADM and disclose a promising therapeutic target to specifically eradicate R-LSCs and overcome relapse in AML.

traducir

CARBONIC ANHYDRASE 1 (CA1) INHIBITORS FOR THE TREATMENT OR PREVENTION OF MYELOPROLIFERATIVE DISORDERS AND OTHER HEMATOPOIETIC MALIGNANCIES, AND AS BIOMARKER OF MYELOPROLIFERATIVE DISORDERS AND OTHER HEMATOPOIETIC MALIGNANCIES

NºPublicación: EP4062909A1 28/09/2022

Solicitante:

COMMISSARIAT ENERGIE ATOMIQUE [FR]
INST NAT SANTE RECH MED [FR]
UNIV PARIS [FR]
UNIV PARIS SACLAY [FR]

WO_2022200613_A2

Resumen de: EP4062909A1

The invention relates to the treatment or prevention of myeloproliferative disorders and other hematopoietic malignancies.Herein is described a carbonic Anhydrase 1 (CA1) inhibitor; for use in a method for treating or preventing a myeloproliferative disorder, an acute myeloid leukemia (AML) and/or a primary or secondary myelofibrosis.Herein is further described the use of carbonic Anhydrase 1 as a biomarker for myeloproliferative disorders and other hematopoietic malignancies; and/or as a biomarker of the efficacy of compounds for treating or preventing said conditions.

traducir

PANELS AND METHODS FOR TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA

NºPublicación: WO2022197930A2 22/09/2022

Solicitante:

BROAD INST INC [US]
DANA FARBER CANCER INST INC [US]
MASSACHUSETTS GEN HOSPITAL [US]

Resumen de: WO2022197930A2

The invention provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.

traducir

B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES

NºPublicación: WO2022194988A2 22/09/2022

Solicitante:

HEIDELBERG PHARMA RES GMBH [DE]

Resumen de: WO2022194988A2

The present application relates to conjugates comprising an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking said amatoxin and said CD37-binding moiety. The invention further relates to the synthesis of said conjugates. In addition, the invention relates to a pharmaceutical composition comprising such conjugate for use in the treatment of immune cell-, particularly B-cell and/or lymphoma associated diseases and/or malignancies.

traducir

PERIPHERAL BLOOD TCR MARKER FOR ACUTE MYELOID LEUKAEMIA, AND TEST KIT AND APPLICATION THEREOF

Nº publicación: WO2022194042A1 22/09/2022

Solicitante:

CHENGDU EXAB BIOTECHNOLOGY CO LTD [CN]

CN_113109564_A

Resumen de: WO2022194042A1

A peripheral blood TCR marker for acute myeloid leukaemia, and a test kit and an application thereof, the marker comprising at least one of the proteins of the sequences shown in SEQ ID NO. 1-100. The present invention is based on a high throughput sequencing method, and only a small amount of peripheral blood needs to be taken; RNA is extracted, an immunoassay library is established by means of processing the samples, and high throughput sequencing and TCR data analysis are performed, first determining characteristic TCR sequences in acute myeloid leukaemia peripheral blood, and then comparing the test result of a sample to be tested with the characteristic TCR sequences to determine whether there is acute myeloid leukaemia; the present invention can simultaneously compare a large number of acute myeloid leukaemia-specific TCR sequences, having higher specificity and accuracy compared to individual detection of one or several markers, and thereby improving diagnosis efficiency.

traducir

Página1 de 4 nextPage por página

punteroimgVolver